Scarica l'app Stockscreener
43.90
0.50%
0.22
Dopo l'orario di chiusura:
43.90
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CORT Giù?
Forum
Previsione
Precedente Chiudi:
$43.68
Aprire:
$43.76
Volume 24 ore:
840.68K
Relative Volume:
0.44
Capitalizzazione di mercato:
$4.67B
Reddito:
$761.41M
Utile/perdita netta:
$98.16M
Rapporto P/E:
53.66
EPS:
0.8181
Flusso di cassa netto:
$141.79M
1 W Prestazione:
+4.85%
1M Prestazione:
+36.55%
6M Prestazione:
-42.85%
1 anno Prestazione:
-36.92%
Intervallo 1D:
$43.27
$44.42
Intervallo di 1 settimana:
$41.00
$44.42
Portata 52W:
$28.66
$91.00
Corcept Therapeutics Inc Stock (CORT) Company Profile
Nome
Corcept Therapeutics Inc
Settore
Industria
Telefono
650.688.8803
Indirizzo
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
43.90 | 4.65B | 761.41M | 98.16M | 141.79M | 0.8181 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-26 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-12-31 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | Iniziato | UBS | Neutral |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-06 | Aggiornamento | Truist | Hold → Buy |
| 2023-04-11 | Iniziato | SVB Securities | Market Perform |
| 2023-04-04 | Iniziato | Piper Sandler | Overweight |
| 2023-02-15 | Downgrade | Jefferies | Buy → Hold |
| 2022-08-01 | Downgrade | Truist | Buy → Hold |
| 2022-07-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-06-27 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-02 | Iniziato | Canaccord Genuity | Buy |
| 2022-01-28 | Iniziato | Truist | Buy |
| 2020-08-05 | Downgrade | Jefferies | Buy → Hold |
| 2019-09-24 | Iniziato | Jefferies | Buy |
| 2019-09-06 | Iniziato | H.C. Wainwright | Buy |
| 2019-02-04 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | Reiterato | Stifel | Hold |
| 2018-05-31 | Downgrade | Stifel | Buy → Hold |
| 2018-03-09 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | Iniziato | Stifel | Buy |
| 2017-02-02 | Iniziato | Ladenburg Thalmann | Buy |
| 2015-04-21 | Iniziato | FBR Capital | Outperform |
| 2014-01-13 | Downgrade | Stifel | Buy → Hold |
| 2013-08-09 | Downgrade | Janney | Buy → Neutral |
| 2013-08-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | Reiterato | JMP Securities | Mkt Outperform |
| 2010-01-06 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | Iniziato | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | Aggiornamento | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Mostra tutto
Corcept Therapeutics Inc Borsa (CORT) Ultime notizie
CORT FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Corcept Therapeutics ... - Caledonian Record
Deadline Alert: Corcept Therapeutics Incorporated (CORT) - GlobeNewswire
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
CORT 1-WEEK DEADLINE ALERT: Hagens Berman Alerts Corcept - GlobeNewswire
CORT 1-WEEK DEADLINE ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Approaching April 21st Lead Plaintiff Deadline in Securities Fraud Class Action Over Relacorilant Failure - GlobeNewswire Inc.
Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors - GlobeNewswire
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - ACCESS Newswire
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Pomerantz LLP Shares Class Action Details With Shareholders in Corcept Therapeutics Incorporated – CORT - ACCESS Newswire
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Approaching April 21st Lead Plaintiff Deadline in Securities Fraud Class Action Over Relacorilant Failure - The Malaysian Reserve
Press releases provided by CNW - Techaeris
Corcept Therapeutics (CORT) climbs 19.7% as Lifyorli gets FDA OK - MSN
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit - PR Newswire
Corcept Leaders Sued Over Drug-Approval Remarks, Stock Sales - Bloomberg Law News
Bragar Eagel & Squire, P.C. Reminds Investors that a Class - GlobeNewswire
Corcept Therapeutics Incorporated Sued for Securities Law - GlobeNewswire
CORT SHAREHOLDER ACTION ALERT: Kaplan Fox Alerts Investors of a Class Action Lawsuit Against Corcept Therapeutics, Inc. (NASDAQ: CORT) and Lead Plaintiff Deadline on April 21, 2026 - NewMediaWire
Corcept's Lifyorli Plus Nab-Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer - National Today
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
How The Corcept Therapeutics (CORT) Investment Story Is Shifting After Legal And Regulatory Updates - Yahoo Finance
Corcept’s Lifyorli shows 35% reduction in death risk for ovarian cancer - Investing.com Australia
DEADLINE ALERT: Kaplan Fox Alerts Investors to a Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT)Deadline is April 21, 2026 - NewMediaWire
FinancialContentDEADLINE ALERT: Kaplan Fox Alerts Investors to a Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT)Deadline is April 21, 2026 - FinancialContent
Corcept Therapeutics (CORT) Unveils Promising Survival Data from ROSELLA Trial - GuruFocus
Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer - Business Wire
1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds - Yahoo Finance
INVESTOR DEADLINE: Corcept Therapeutics (CORT) Investors - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Corcept - GlobeNewswire
CORT Shareholder Alert: Corcept Therapeutics Incorporated Securities Class Action Lawsuit ... - Bluefield Daily Telegraph
CORT Shareholder Alert: Corcept Therapeutics Incorporated - GlobeNewswire
Securities Class Action Deadline Against Corcept Therapeutics, Inc. (NASDAQ: CORT)Contact Kaplan Fox Before April 21, 2026 - FinancialContent
Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL) and Corcept Therapeutics (CORT) - The Globe and Mail
CORT Stock Price, Quote & Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
Deadline Alert: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - GlobeNewswire
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
CORT DEADLINE ALERT: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Corcept Therapeutics, Inc. (NASDAQ: CORT) and Lead Plaintiff Deadline on April 21, 2026 - NewMediaWire
CORT Investors Have Opportunity to Lead Corcept - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming DeadlinesCORT - PR Newswire
Corcept therapeutics officer Guyer sells $819k in shares By Investing.com - Investing.com UK
Corcept (NASDAQ: CORT) CDO sells 20,000 shares after option exercise - Stock Titan
Corcept (CORT) director Wilson reports 5,000-share stock gift via trust - Stock Titan
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Inve - The National Law Review
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics - GlobeNewswire
CORT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Corcept Therapeutics Incorporated Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
CORT INVESTOR ALERT: Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) Are Encouraged to Contact Kaplan Fox Before Lead Plaintiff Deadline on April 21, 2026 - FinancialContent
Corcept Therapeutics Inc (NASDAQ:CORT): An Affordable Growth Stock Built on a Strong Foundation - ChartMill
Corcept Therapeutics Incorporated Securities Fraud Class - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT - ChartMill
Corcept (CORT) Class Action Alleges Misstatements on FDA Data ConcernsHagens Berman - ChartMill
Insider sells 20,000 CORT shares after option exercise (CORT) - Stock Titan
CORT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Corcept Therapeutics Incorporated Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Corcept Therapeutics Inc Azioni (CORT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):